Herbal Patch for Overactive Bladder

Status Completed

Clinical Trial Summary

Clinical Trial Description

Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.

The 1st year project: (1) Expect to enroll 62 clinical subjects of OAB. (2) Evaluate subjects 'symptom and proceed patch treatment. (3) Record treatment responses including adverse effect. (4) Conduct statistically analysis.

The 2nd year project: (1) Completing enrollment of 62 clinical subjects of OAB. (2) Finish evaluation and treatment of all subjects. (3) Statistically analysis all collecting data (4) Discuss and analyze the outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03532789
Study type	Interventional
Source	En Chu Kong Hospital
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	May 14, 2018
Completion date	October 23, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02540707` - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes	Phase 4
Not yet recruiting	`NCT05977634` - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder	N/A
Not yet recruiting	`NCT06438861` - Role of Combination Therapy in Women With Refractory Overactive Bladder	N/A
Completed	`NCT01114412` - Basic Sensations Coming From the Bladder
Recruiting	`NCT06045728` - Telerehabilitation for Overactive Bladder Syndrome in Obese Women	N/A
Recruiting	`NCT03952299` - Oxybutynin for Post-surgical Bladder Pain and Urgency	Phase 3
Active, not recruiting	`NCT03758235` - Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin	Phase 3
Completed	`NCT01912885` - Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome	N/A
Completed	`NCT04300400` - Treatment of the Overactive Bladder Syndrome: A Delphi Study
Recruiting	`NCT04982120` - Use of Repris Needle in Bladder Injection	N/A
Completed	`NCT06123364` - Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder	N/A
Recruiting	`NCT06088394` - Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder	N/A
Recruiting	`NCT05221021` - Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome	Phase 4
Terminated	`NCT04256876` - TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)	N/A
Not yet recruiting	`NCT03331081` - Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome	N/A
Recruiting	`NCT04873037` - BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder	N/A
Completed	`NCT02024945` - Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome	Phase 4
Completed	`NCT00546637` - Fesoterodine "add-on" Male Overactive Bladder Study	Phase 3
Not yet recruiting	`NCT06143397` - Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.	N/A
Recruiting	`NCT03044912` - Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.